1949P Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for treatment-naïve advanced PD-L1-positive NSCLC: Results from the phase II MK-2870-003/SKB264-II-04 study
Year: 2025
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Sun Yat-sen University Cancer Center, Sichuan Cancer Hospital, First Hospital of China Medical University, First Affiliated Hospital of Zhengzhou University, Jilin Province Tumor Hospital, Third Affiliated Hospital of Harbin Medical University, West China Hospital of Sichuan University, Fujian Provincial Cancer Hospital, Shanghai Chest Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Hunan Cancer Hospital, First Affiliated Hospital Zhejiang University, Zhejiang University, Peking University Cancer Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Kelun Group (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Merck Sharp and Dohme
OpenAlex ID: W4415940906
